Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology ๐ and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.
Publication Profile
Scopus
Education
Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 ๐ง ๐. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 ๐ฅ๐. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 ๐ฌ๐งช. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.
Awards
Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field ๐ง ๐. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Whoโs Who in Science and Engineering for her scientific impact ๐๐. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.
Research Focus
Dr. Vibeke Strandโs research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib ๐๐. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies ๐๐ผ. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.
Publication Top Notes
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial
Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms
How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)
Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents